GRDN - Guardian Pharmacy S... Stock Analysis | Stock Taper
Logo
Guardian Pharmacy Services, Inc.

GRDN

Guardian Pharmacy Services, Inc. NYSE
$36.93 -0.43% (-0.16)

Market Cap $2.35 B
52w High $41.36
52w Low $19.17
P/E 47.35
Volume 317.64K
Outstanding Shares 63.34M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $397.62M $27.85M $20.92M 5.26% $0.33 $42.34M
Q3-2025 $377.43M $58.37M $9.82M 2.6% $0.16 $23.61M
Q2-2025 $344.33M $55.57M $9.03M 2.62% $0.15 $18.25M
Q1-2025 $329.31M $51.34M $9.45M 2.87% $0.15 $18.54M
Q4-2024 $338.57M $50.35M $11.94M 3.53% $0.2 $21.8M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $65.62M $412.66M $194.73M $205.76M
Q3-2025 $36.49M $390.04M $194.54M $183.76M
Q2-2025 $18.82M $356.33M $176.66M $169.56M
Q1-2025 $14M $334M $170.78M $156.09M
Q4-2024 $4.66M $320.81M $170.83M $142.67M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $21.27M $34.6M $-4.36M $-1.11M $29.13M $30.37M
Q3-2025 $9.59M $28.17M $-8.97M $-1.53M $17.67M $22.96M
Q2-2025 $8.83M $19.94M $-13M $-2.11M $4.82M $15.63M
Q1-2025 $9.27M $17.55M $-5.54M $-2.67M $9.34M $11.74M
Q4-2024 $11.94M $22.34M $-6.62M $-48.27M $-32.56M $17.84M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025Q4-2025
Corporate Segment
Corporate Segment
$330.00M $340.00M $380.00M $400.00M

Q4 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at Guardian Pharmacy Services, Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

Guardian combines a sizable, recurring revenue base with clear profitability, strong cash generation, and a conservative balance sheet featuring low debt and ample liquidity. Its specialized focus on assisted living and behavioral health, supported by proprietary technology and a hybrid local‑plus‑national model, creates a differentiated service offering. The company’s ability to convert earnings into cash, reinvest in operations, and still grow its cash balance underscores solid financial discipline and operational execution.

! Risks

Key risks stem from operating in a low‑margin, highly regulated healthcare niche that is exposed to reimbursement changes, regulatory shifts, and consolidation among long‑term care providers. Intangible assets and goodwill tied to acquisitions could be vulnerable if acquired units underperform. High overhead relative to revenue leaves limited margin for error if volumes or pricing come under pressure. In addition, heavy reliance on internal technology and data systems means that execution missteps, cybersecurity issues, or lagging innovation versus larger competitors could erode advantages over time.

Outlook

Based on the available data, Guardian appears financially sound and competitively well positioned within its chosen niches, with strong cash flow and a balance sheet that can support continued investment and selective growth. Future performance will likely depend on its ability to maintain reimbursement levels, deepen relationships with long‑term care facilities, keep innovating its technology and analytics platforms, and integrate any additional acquisitions smoothly. With only one year of detailed financials, visibility into long‑term trends is limited, but the current snapshot suggests a stable platform with both opportunities and execution risks ahead.